By VALIDOGEN GmbH
To get in touch with VALIDOGEN GmbH, simply fill out the form below.
Subscribe to Supplier
VTU bringing advanced protein expression to BIO-Europe
Grambach, Austria: – Protein expression specialist VTU Technology will use November’s BIO-Europe biotechnology partnering conference in Germany to recruit new partners to exploit its world-leading Pichia pastoris recombinant platform.
Dr. Thomas Purkarthofer, VTU’s Head of Business Development, will represent VTU in Munich. He will be able to provide detailed information on this next generation protein expression technology, along with other innovations and services.
Dr. Purkarthofer said he would use BIO-Europe’s PartneringONE system to arrange a series of meetings throughout the three-day event. He is hoping to discuss technology transfers and out licensing opportunities for Human Serum Albumin (HSA), Human Serum Transferrin (HST), HSA-fusion, cell culture proteins and among others.
“Alongside BIO, this is Europe’s most important Biotech partnering conference, which is why we’ve been regular attenders at BIO-Europe ever since 2009,” said Dr. Purkarthofer.
“We’re reaching out pharmaceutical and veterinary companies, food, chemical and biotechnology companies with the potential to exploit our powerful protein expression toolbox and highly versatile Pichia pastoris technology platform,” said Dr. Purkarthofer.
“Together, these have combined to enable us achieve the highest protein expression productivities ever reported – up to 35 grams per liter,” he added. Recently, VTU broke through the 20 g/l barrier in methanol-free protein processing.
Pichia pastoris protein expression excellence VTU Technology will also use BIO-Europe to present its high-speed expression strain development, fermentation process development and optimization, downstream and analytical process development and production of purified non-GMP material.
Dr. Purkarthofer confirmed that VTU’s versatile and powerful Pichia protein expression platform enables it to meet tight development timelines.
“We can deliver cost-effective and robust production processes that carry zero risk of viral or endotoxin contamination,” said Dr. Purkarthofer.
About VTU Technology
VTU Technology is a leading service provider for the fast track development of protein expression strains and protein production processes often yielding up to 25 g/L of secreted protein (recently reaching 35 g/l of secreted protein ) for a wide range of biologics and other proteins.
VTU Technology´s powerful Pichia pastoris protein expression technology platform is based on its exclusive AOX1 promoter libraries and in-house expression platform, complemented by its optimized gene design and cloning strategies as well as high-throughput screening and cultivation regime, combined with excellent know-how in fermentation and downstream process development.
Headquartered in Grambach, near Graz, Austria, VTU Technology is a private company and a subsidiary of VTU Holding, an Austrian enterprise that combines several technology and engineering companies in pharma and life sciences, chemistry and energy.
About BIO-Europe 2015
The BIO-Europe® Conference is the flagship conference for EBD Group, providing life science companies with high caliber knowledge sharing and partnering opportunities.
BIO-Europe 2015 event is a three-day event opening November 2 at Munich’s ICM international conference center.
BIO-Europe has formed the launchpad for many highly successful business partnerships, drawing delegates from all parts of the biotechnology value chain to identify, engage and enter into strategic relationships.
This year´s BIO-Europe partnering event will again draw over 3,000 industry attendees from nearly 60 countries, representing more than 1,800 companies for three days of high level networking.
Partnering at BIO-Europe 2015 is powered by EBD Group’s partneringONE®, the industry’s most advanced networking system, which enables participants to efficiently mine a large pool of potential partners, and identify and pre-arrange private one-to-one meetings with multiple company targets.
More information at: http://www.ebdgroup.com/bioeurope/index.php